TB status in a dynamic cohort of patients with Inflammatory Bowel Disease receiving immunosuppression treatment, with up to 8 years of follow-up.

M. Arias Guillen (Oviedo, Spain), R. De Francisco (Oviedo, Spain), S. Riestra-Menéndez (Oviedo, Spain), G. Muñiz-Albaiceta (Oviedo, Spain), M. González-Budiño (Oviedo, Spain), M. García-Clemente (Oviedo, Spain), C. Del Busto (Oviedo, Spain), M. Santibáñez-Margüello (Santander, Spain), A. Castaño-García (Oviedo, Spain), S. Martínez-González (Oviedo, Spain), C. Huidobro (Oviedo, Spain), L. Pérez-González (Oviedo, Spain), I. Ruiz-Alvarez (Oviedo, Spain), J. Herrero-Huertas (Oviedo, Spain), P. Ugarriza (Oviedo, Spain), V. Jiménez-Beltrán (Oviedo, Spain), P. Flórez-Díez (Oviedo, Spain), N. Rodríguez (Oviedo, Spain), C. Bailón (Oviedo, Spain), S. Gómez-Mañas (Oviedo, Spain), A. Losada-Dieguez (Oviedo, Spain), P. Escalante (Ro,MN, United States of America)

Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Session: Tuberculosis and non-TB mycobacterial infection I
Session type: Oral Presentation
Number: 3818
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Arias Guillen (Oviedo, Spain), R. De Francisco (Oviedo, Spain), S. Riestra-Menéndez (Oviedo, Spain), G. Muñiz-Albaiceta (Oviedo, Spain), M. González-Budiño (Oviedo, Spain), M. García-Clemente (Oviedo, Spain), C. Del Busto (Oviedo, Spain), M. Santibáñez-Margüello (Santander, Spain), A. Castaño-García (Oviedo, Spain), S. Martínez-González (Oviedo, Spain), C. Huidobro (Oviedo, Spain), L. Pérez-González (Oviedo, Spain), I. Ruiz-Alvarez (Oviedo, Spain), J. Herrero-Huertas (Oviedo, Spain), P. Ugarriza (Oviedo, Spain), V. Jiménez-Beltrán (Oviedo, Spain), P. Flórez-Díez (Oviedo, Spain), N. Rodríguez (Oviedo, Spain), C. Bailón (Oviedo, Spain), S. Gómez-Mañas (Oviedo, Spain), A. Losada-Dieguez (Oviedo, Spain), P. Escalante (Ro,MN, United States of America). TB status in a dynamic cohort of patients with Inflammatory Bowel Disease receiving immunosuppression treatment, with up to 8 years of follow-up.. 3818

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: